Sign in

CIK 0001806952

  • Non-accelerated filer
  • Smaller reporting company

Lyell Immunopharma, Inc.

Sign in to watch
Ticker
LYEL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
833006753
Phone
+1 650-695-0677
Business address
201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Open-market sale President and CEO sold 7,455 shares at $23.39 ($174,372)
  2. 4 Open-market sale Chief Operating Officer sold 1,236 shares at $23.39 ($28,910)
  3. 4 Open-market sale Chief Scientific Officer sold 1,671 shares at $23.39 ($39,085)
  4. 4 Open-market sale Chief Operating Officer sold 109 shares at $23.12 ($2,520)
  5. 4 Open-market sale Chief Scientific Officer sold 147 shares at $23.12 ($3,399)
  6. 4 Open-market sale President and CEO sold 438 shares at $23.12 ($10,127)
  7. 4 Derivatives Options or other derivatives
  8. 4 Open-market sale VP, Corporate Controller sold 254 shares at $23.12 ($5,872)
  9. 4 Derivatives Options or other derivatives
  10. 4 Open-market sale VP, Corporate Controller sold 2,072 shares at an average $35.80 ($74,181)
  11. 4 Open-market sale President and CEO sold 412 shares at $16.11 ($6,637)
  12. 4 Open-market sale VP, Corporate Controller sold 239 shares at $16.10 ($3,848)
  13. 4 Open-market sale Chief Scientific Officer sold 138 shares at $16.16 ($2,230)
  14. 4 Open-market sale Chief Operating Officer sold 95 shares at $16.12 ($1,531)
  15. 3 Insider Initial Statement of Ownership
  16. 4 Derivatives Options or other derivatives
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 4 Open-market sale President and CEO sold 7,257 shares at $10.54 ($76,518)
  20. 4 Open-market sale Chief Operating Officer sold 1,004 shares at $10.54 ($10,586)

Page 3 of 9 · 173 filings